Advances in atopic dermatitis and urticarial in 2016

This review highlights recent key advances in the pathology and therapies of inflammatory skin diseases, focusing on atopic dermatitis (AD) and chronic spontaneous urticaria (CSU). Regarding AD, transcriptomic analysis with human samples revealed different immune profiles between childhood and adult AD. Phase III clinical trials of dupilumab, an anti–IL-4 receptor α antibody, in the treatment of AD have successfully finished, and dupilumab will appear in clinical practice as the first biologic for AD in 2017. In addition, a novel biologic that targets IL-31 shows promising results in a phase II trial. As for the skin microbiome study, novel insights into the mechanisms of microbial dysbiosis, such as colonization of Staphylococcus aureus, a common feature of AD, were proposed. Regarding CSU, autoreactive CD4+ T cells that react to FcεRI were discovered, which might contribute to the development of CSU. These findings provide new insights into the pathogenesis of AD and CSU and will lead to more specific and personalized treatments.

Key words

Atopic dermatitis
chronic spontaneous urticaria
biologics
microbiome
biomarker
transcriptome

Abbreviations used

AD
Atopic dermatitis
AMP
Antimicrobial peptide
CRTH2
Chemoattractant receptor–homologous molecule expressed on TH2 cells
CSU
Chronic spontaneous urticaria
DC
Dendritic cell
IBD
Inflammatory bowel disease
LC
Langerhans cell
peTH2
Pathogenic effector TH2
RA
Rheumatoid arthritis
RCT
Randomized controlled trial
T1D
Type 1 diabetes
Treg
Regulatory T
TSLP
Thymic stromal lymphopoietin
UCA
Urocanic acid

Autor / Fonte:Tetsuya Honda, Takashi Nomura, Kenji Kabashima Journal of Allergy and Clinical Immunology 2017 June 23
Link: http://www.sciencedirect.com/science/article/pii/S0091674917310229